Literature DB >> 8221523

Laboratory diagnostic methods in Lyme borreliosis.

K Hansen1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221523     DOI: 10.1016/0738-081x(93)90097-v

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


× No keyword cloud information.
  6 in total

1.  Enzyme-linked immunosorbent assay using recombinant OspC and the internal 14-kDa flagellin fragment for serodiagnosis of early Lyme disease.

Authors:  S Rauer; N Spohn; C Rasiah; U Neubert; A Vogt
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

2.  Recombinant assay for serodiagnosis of Lyme disease regardless of OspA vaccination status.

Authors:  Maria J C Gomes-Solecki; Gary P Wormser; Martin Schriefer; Glenn Neuman; Laura Hannafey; John D Glass; Raymond J Dattwyler
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

3.  Transformation of cystic forms of Borrelia burgdorferi to normal, mobile spirochetes.

Authors:  O Brorson; S H Brorson
Journal:  Infection       Date:  1997 Jul-Aug       Impact factor: 3.553

4.  Establishment of enzyme-linked immunosorbent assay using purified recombinant 83-kilodalton antigen of Borrelia burgdorferi sensu stricto and Borrelia afzelii for serodiagnosis of Lyme disease.

Authors:  S Rauer; M Kayser; U Neubert; C Rasiah; A Vogt
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

5.  The outer surface proteins of Lyme disease borrelia spirochetes stimulate T cells to secrete interferon-gamma (IFN-gamma): diagnostic and pathogenic implications.

Authors:  P Forsberg; J Ernerudh; C Ekerfelt; M Roberg; M Vrethem; S Bergström
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

6.  Analysis of the intrathecal immune response in neuroborreliosis to a sonicate antigen and three recombinant antigens of Borrelia burgdorferi sensu stricto.

Authors:  R Kaiser; S Rauer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.